Results 151 to 160 of about 18,378,232 (237)

Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study. [PDF]

Biomed Res Int
Shanka NY, Pavlov CS, Turankova TA, Ajabo TT, Nigatu LM, Dana BE.   +5 more
europepmc   +1 more source

Performance of native and gadoxetate-enhanced liver and spleen T₁ mapping for noninvasive diagnosis of clinically significant portal hypertension: preliminary results. [PDF]

Abdom Radiol (NY), 2022
Altinmakas E, Bane O, Hectors SJ, Issa R, Carbonell G, Abboud G, Schiano TD, Thung S, Fischman A, Kelly MD, Friedman SL, Kennedy P, Taouli B.   +12 more
europepmc   +1 more source

Diagnostic challenges of clinically significant portal hypertension in geriatric metabolic dysfunction-associated fatty liver disease: A case report. [PDF]

World J Hepatol
Akbar FN, Darnindro N, Wardhani AA, Choirida SR, Saphira SN, Ismed G, Kshanti IAM, Mustika S, Hendarto H.   +8 more
europepmc   +1 more source

Network Meta-Analysis: Noninvasive Imaging Modalities for Identifying Clinically Significant Portal Hypertension. [PDF]

Dig Dis Sci, 2022
Hai Y, Chong W, Eisenbrey JR, Forsberg F.   +3 more
europepmc   +1 more source

Addressing Long‐Tailed Drug–Drug Interactions Through Minimisation of Predictive Uncertainty and Loss Sharpness

CAAI Transactions on Intelligence Technology, EarlyView.
ABSTRACT Drug–Drug Interaction (DDI) prediction is critical for ensuring patient safety, particularly under long‐tailed distributions, where frequent (head) interactions dominate whereas rare (tail) interactions remain underrepresented. Conventional loss functions such as cross‐entropy often tend to overfit head classes while they underperform on rare ...
Chao Liu, Xizhao Wang, Farhad Pourpanah, Sam Kwong   +3 more
wiley   +1 more source

Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertension. [PDF]

Hepatobiliary Surg Nutr
Semmler G, Jachs M, Mandorfer M.
europepmc   +1 more source

The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis. [PDF]

Trials, 2023
Reiberger T, Berzigotti A, Trebicka J, Ertle J, Gashaw I, Swallow R, Tomisser A.   +6 more
europepmc   +1 more source

Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes, Rishi S. Kotecha, Derek J. Roebuck   +2 more
wiley   +1 more source

Understanding clinically significant portal hypertension: an in-depth look at pathogenesis, diagnosis and treatment. [PDF]

Ann Gastroenterol
Vanderschueren E, van der Merwe S, Laleman W.   +2 more
europepmc   +1 more source

Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour, Melanie Faugere, Laurent Boyer, Christophe Lançon, Theo Korchia   +4 more
wiley   +1 more source